Groundbreaking Platform first applied to rare autoimmune disorder, IgG4-RD to uncover new treatment targets

Differentia Biotech, a leader in model-informed drug development, is proud to announce the launch of its innovative autoimmune disease platform. This platform integrates Artificial Intelligence and Machine Learning (AI/ML) with Quantitative Systems Pharmacology (QSP) extracting disease understanding by combining insights from patient-specific multiomic datasets and literature.

This pioneering platform marks a significant advancement in the understanding and treatment of autoimmune diseases, enabling target identification and validation, lead optimization, biomarker discovery and clinical trial design.

For more detail see Link: Differentia Biotech Launches Cutting-Edge Autoimmune Disorder Platform Combining AI/ML with QSP.